PMID- 38434915
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240305
IS  - 2732-7787 (Electronic)
IS  - 2732-7787 (Linking)
VI  - 4
IP  - 2
DP  - 2024 Mar-Apr
TI  - NK and T-lymphocyte Kinetics Predict Outcome in Myeloma Patients Treated With 
      Elotuzumab, Lenalidomide Plus Dexamethasone.
PG  - 97-104
LID - 10.21873/cdp.10293 [doi]
AB  - BACKGROUND/AIM: Elotuzumab, an anti-SLAMF7 monoclonal antibody, can enhance 
      immune activity via elevated antibody-dependent cellular cytotoxicity and reduced 
      SLAMF7(+)CD8(+)CD57(+) regulatory T-cells (Tregs). This multicenter observational 
      study investigated the kinetics of lymphocytes in myeloma patients treated with 
      elotuzumab, lenalidomide, and dexamethasone (ERd) by two-color flow cytometry 
      using peripheral blood samples. PATIENTS AND METHODS: Twenty-one patients were 
      included in this study. The median duration of ERd was 22.6 months, and the 
      cutoff time for long-duration ERd was two years. RESULTS: The CD2(+)CD16(+) and 
      CD16(+)CD57(-) NK cells were significantly increased over time in the 
      long-duration ERd group compared to those in the short-duration ERd group 
      (p=0.035 and p<0.001). The CD8(+) and CD16(-)CD57(+) lymphocytes, identified as 
      low-activity NK cells or SLAMF7(+) Tregs, were significantly increased in the 
      patients whose ERd outcome was progressive disease (PD) compared to those in the 
      non-PD group (p=0.023 and p<0.001). The mean CD4/CD8 ratio and CD19(+) lymphocyte 
      counts in the long-duration ERd group were significantly lower than those in the 
      short-duration ERd group, although the kinetics of them did not change over time 
      (p=0.016 and p=0.011). When the cutoff value of CD4/CD8 ratio was 0.792 according 
      to ROC curves, the two-year time to next treatment (TTNT) in the low CD4/CD8 
      group was significantly longer than that in the high CD4/CD8 group (80.0% vs. 
      15.0%, p=0.024). CONCLUSION: The change in NK cells and CD8(+) Tregs predicted 
      long-duration ERd and PD, and maintaining low CD4/8 ratio predicted long TTNT, 
      suggesting that these lymphocyte fractions might be biomarkers for a durable 
      therapeutic effect of ERd in myeloma patients.
CI  - Copyright 2024, International Institute of Anticancer Research.
FAU - Suzuki, Kazuhito
AU  - Suzuki K
AD  - Division of Clinical Oncology/Hematology, Department of Internal Medicine, The 
      Jikei University School of Medicine, Tokyo, Japan.
FAU - Matsumoto, Morio
AU  - Matsumoto M
AD  - Department of Hematology, Shibukawa Medical Center, Gunma, Japan.
FAU - Hiramatsu, Yasushi
AU  - Hiramatsu Y
AD  - Department of Hematology/Oncology, Japanese Red Cross Society Himeji Hospital, 
      Hyogo, Japan.
FAU - Takezako, Naoki
AU  - Takezako N
AD  - Department of Hematology, National Hospital Organization Disaster Medical Center, 
      Tokyo, Japan.
FAU - Tamai, Yotaro
AU  - Tamai Y
AD  - Department of Hematology, Shonan Kamakura General Hospital, Kanagawa, Japan.
FAU - Suzuki, Kenshi
AU  - Suzuki K
AD  - Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
LA  - eng
PT  - Journal Article
DEP - 20240303
PL  - Greece
TA  - Cancer Diagn Progn
JT  - Cancer diagnosis & prognosis
JID - 9918316186306676
PMC - PMC10905294
OTO - NOTNLM
OT  - CD4/8
OT  - Elotuzumab
OT  - multiple myeloma
OT  - natural killer cell
OT  - regulatory T cell
COIS- K. Suzuki received personal fees from Takeda Pharmaceutical Company, Janssen 
      Pharmaceutical K.K., Sanofi, Celgene, outside the submitted work; M. Matsumoto 
      received honoraria from Bristol-Myers Squibb K.K., Janssen Pharmaceutical and 
      Takeda Pharmaceutical, Ono Pharmaceutical, Sanofi K.K., outside the submitted 
      work; K. Suzuki received honoraria from Takeda, ONO, Amgen, Novartis, Sanofi, 
      Bristol-Myers Squibb, Abbvie and Janssen, consulted for Amgen, Takeda, and 
      Bristol-Myers Squibb, and received research funding from Bristol-Myers Squibb. 
      The other Authors declare that they have no conflicts of interest.
EDAT- 2024/03/04 06:47
MHDA- 2024/03/04 06:48
PMCR- 2024/03/03
CRDT- 2024/03/04 04:52
PHST- 2023/12/06 00:00 [received]
PHST- 2024/01/22 00:00 [accepted]
PHST- 2024/03/04 06:48 [medline]
PHST- 2024/03/04 06:47 [pubmed]
PHST- 2024/03/04 04:52 [entrez]
PHST- 2024/03/03 00:00 [pmc-release]
AID - 10.21873/cdp.10293 [doi]
PST - epublish
SO  - Cancer Diagn Progn. 2024 Mar 3;4(2):97-104. doi: 10.21873/cdp.10293. eCollection 
      2024 Mar-Apr.